Indivior Pharmaceuticals (INDV) Income from Continuing Operations (2024 - 2026)

Indivior Pharmaceuticals has reported Income from Continuing Operations for 3 years, with the latest figure at $122.0 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations rose 577.78% year-over-year to $122.0 million in Q2 2026; TTM through Jun 2026 was $355.0 million, a 225.69% increase from a year earlier, with the FY2025 full-year figure at $210.0 million, up 2900.0% from the prior year.
• Income from Continuing Operations was $122.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $89.0 million in the prior quarter.
• The five-year high for Income from Continuing Operations was $122.0 million in Q2 2026, with the low at -$98.0 million in Q2 2024.
• Average Income from Continuing Operations over 3 years is $42.8 million, with a median of $45.0 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations slipped 22.58% in 2025, then jumped 577.78% in 2026.
• Over 3 years, Income from Continuing Operations stood at $21.0 million in 2024, then jumped by 385.71% to $102.0 million in 2025, then increased by 19.61% to $122.0 million in 2026.
• The last three Income from Continuing Operations figures came in at $122.0 million (Q2 2026), $89.0 million (Q1 2026), and $102.0 million (Q4 2025), per Business Quant data.